Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › BEIGENE, LTD. › 18099319
Last updated: April 19, 2026
Application No. 18/099,319

ORAL CAPSULE AND PREPARATION METHOD THEREFOR

Final Rejection
Filed
Jan 20, 2023
Examiner
KUCHARCZK, JED A
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BEIGENE, LTD.
OA Round
5 (Final)
80%
Grant Probability
Favorable
6-7
OA Rounds
2y 7m
To Grant
99%
With Interview

Interview Optional

— +20.9% interview lift. This examiner has a relatively high allow rate; a written response may suffice.
Based on 85 resolved cases, 2023–2026

Examiner Intelligence

KUCHARCZK, JED A View full profile →
Grants 80% — above average
80%
Career Allow Rate
68 granted / 85 resolved
+20.0% vs TC avg
Strong +21% interview lift
Without
With
+20.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
32 currently pending
Career history
117
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
31.6%
-8.4% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 85 resolved cases

Prosecution Timeline

Jan 20, 2023
Application Filed
Jan 20, 2023
Response after Non-Final Action
Apr 04, 2023
Response after Non-Final Action
Apr 14, 2023
Examiner Interview (Telephonic)
May 03, 2023
Non-Final Rejection
May 16, 2023
Applicant Interview (Telephonic)
Aug 09, 2023
Response Filed
Oct 13, 2023
Final Rejection
Jan 12, 2024
Final Rejection
Apr 03, 2024
Response after Non-Final Action
Apr 30, 2024
Examiner Interview (Telephonic)
Apr 30, 2024
Response after Non-Final Action
Jun 14, 2024
Request for Continued Examination
Jun 20, 2024
Response after Non-Final Action
Oct 07, 2024
Response Filed
Jan 30, 2025
Non-Final Rejection
Jul 03, 2025
Response Filed
Oct 01, 2025
Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/286,716
Patent 12600710
BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS
2y 5m to grant Granted Apr 14, 2026
18/049,966
Patent 12599617
METHODS OF TREATING HEAD AND NECK CANCERS WITH HEMP EXTRACT
2y 5m to grant Granted Apr 14, 2026
17/684,164
Patent 12595253
BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
2y 5m to grant Granted Apr 07, 2026
18/510,546
Patent 12577260
BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 17, 2026
17/351,970
Patent 12570645
USES OF P53 X-RAY CO-CRYSTAL STRUCTURES
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

6-7
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+20.9%)
2y 7m
Median Time to Grant
High
PTA Risk
Based on 85 resolved cases by this examiner. Grant probability derived from career allow rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month